Literature DB >> 29943201

Beyond 35 years of Parkinson's disease: a comprehensive clinical and instrumental assessment.

Alberto Romagnolo1, Margherita Fabbri2,3, Aristide Merola4, Elisa Montanaro2, Sara Palermo5, Tiziana Martone2, Agostino Seresini6, Stefano Goldwurm2,7, Mario Giorgio Rizzone2, Leonardo Lopiano2.   

Abstract

BACKGROUND: We sought to characterize the clinical, neuropsychological, electrophysiological, and neuroimaging features of Parkinson's disease (PD) after over 35 years since the onset of motor symptoms.
METHODS: Five consecutively consenting PD patients treated with subthalamic nucleus deep brain stimulation (STN-DBS) were recruited in a cross-sectional study of motor (Unified PD Rating Scale section-III), non-motor (Non-Motor Symptoms Scale), autonomic (Scale for Outcome in PD-Autonomic), and neuropsychological features associated with the very advanced phase of PD. In addition, patients underwent neurophysiological (autonomic tests and nerve conduction studies) and neuroimaging (brain MRI, 123I-FP-CIT SPECT, and 123I-MIBG myocardial scintigraphy) studies, as well as a genetic analysis of 34 genes and single nucleotide polymorphisms associated with PD.
RESULTS: There was a sustained motor response to L-dopa (range 14.4-35.6%), STN-DBS (23.3-38.4%), and L-dopa plus STN-DBS (37.8-63.0%). There were mild-to-moderate non-motor symptoms (range 19-83 on a scale of 0 to 360) and autonomic dysfunction (8-28 on a scale of 0-69). Two patients were demented, one had mild cognitive impairment, and two were cognitively preserved. Three patients had a sensory-axonal peripheral neuropathy and two a moderate-to-severe autonomic neuropathy. All cases showed a complete nigro-striatal dopaminergic denervation and a severe cardiovascular noradrenergic denervation. The brain MRI revealed only moderate frontal atrophy. The genetic tests were unremarkable.
CONCLUSIONS: Even after more than 35 years of disease, L-dopa  and STN-DBS remain effective on PD cardinal symptoms. Although axial, autonomic, and neuropsychological features may become key determinants of disability, some patients maintain a satisfactory quality of life, without significant motor and non-motor impairment.

Entities:  

Keywords:  Deep brain stimulation; Late stage; Parkinson’s disease

Mesh:

Year:  2018        PMID: 29943201     DOI: 10.1007/s00415-018-8955-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

Authors:  Kallol Ray Chaudhuri; Pablo Martinez-Martin; Richard G Brown; Kapil Sethi; Fabrizio Stocchi; Per Odin; William Ondo; Kazuo Abe; Graeme Macphee; Doug Macmahon; Paolo Barone; Martin Rabey; Alison Forbes; Kieran Breen; Susanne Tluk; Yogini Naidu; Warren Olanow; Adrian J Williams; Sue Thomas; David Rye; Yoshio Tsuboi; Annette Hand; Anthony H V Schapira
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

2.  EFNS guidelines on the diagnosis and management of orthostatic hypotension.

Authors:  H Lahrmann; P Cortelli; M Hilz; C J Mathias; W Struhal; M Tassinari
Journal:  Eur J Neurol       Date:  2006-09       Impact factor: 6.089

3.  Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study.

Authors:  Roberto Ceravolo; Giovanni Cossu; Monica Bandettini di Poggio; Lucio Santoro; Paolo Barone; Maurizio Zibetti; Daniela Frosini; Valentina Nicoletti; Fiore Manganelli; Rosa Iodice; Marina Picillo; Aristide Merola; Leonardo Lopiano; Alessandra Paribello; Davide Manca; Maurizio Melis; Roberta Marchese; Paolo Borelli; Alessandra Mereu; Paolo Contu; Giovanni Abbruzzese; Ubaldo Bonuccelli
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

4.  Subthalamic deep brain stimulation: clinical and neuropsychological outcomes in mild cognitive impaired parkinsonian patients.

Authors:  Aristide Merola; Laura Rizzi; Carlo Alberto Artusi; Maurizio Zibetti; Mario Giorgio Rizzone; Alberto Romagnolo; Andrea Bernardini; Michele Lanotte; Leonardo Lopiano
Journal:  J Neurol       Date:  2014-06-22       Impact factor: 4.849

5.  Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.

Authors:  Aristide Merola; Maurizio Zibetti; Serena Angrisano; Laura Rizzi; Valeria Ricchi; Carlo A Artusi; Michele Lanotte; Mario G Rizzone; Leonardo Lopiano
Journal:  Brain       Date:  2011-06-11       Impact factor: 13.501

6.  The Dysphagia Outcome and Severity Scale.

Authors:  K H O'Neil; M Purdy; J Falk; L Gallo
Journal:  Dysphagia       Date:  1999       Impact factor: 3.438

Review 7.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

8.  Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants.

Authors:  Alfonso Fasano; Luigi M Romito; Antonio Daniele; Carla Piano; Massimiliano Zinno; Anna Rita Bentivoglio; Alberto Albanese
Journal:  Brain       Date:  2010-09       Impact factor: 13.501

9.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 10.  Apathy: a neuropsychiatric syndrome.

Authors:  R S Marin
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

View more
  2 in total

1.  Risk factors for motor complications in female patients with Parkinson's disease.

Authors:  Zhirong Wan; Xuemei Wang; Huizi Ma; Zhan Wang; Tao Feng
Journal:  Neurol Sci       Date:  2022-04-06       Impact factor: 3.830

Review 2.  Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease.

Authors:  Margherita Fabbri; Linda Azevedo Kauppila; Joaquim J Ferreira; Olivier Rascol
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.